Przegląd Gastroenterologiczny

Treatment of inflammatory bowel diseases (IBD) in primary sclerosing cholangitis (PSC)/IBD patients with co-existing PSC

  1. Department of Oncological Gastroenterology, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

  2. Department of Gastroenterology, Hepatology, and Clinical Oncology, Centre of Postgraduate Medical Education, Warsaw, Poland

Gastroenterology Rev

Data publikacji online: 2026/11/09
Article file
Treatment of inflammatory (1).pdf
  1. Tsaitas C, Semertzidou A, Sinakos E. Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol 2014; 6: 178-87.
  2. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 31-9.
  3. Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol 2011; 7: 235-41.
  4. Rossi RE, Conte D, Massironi S. Primary sclerosing cholangitis associated with inflammatory bowel disease: an update. Eur J Gastroenterol Hepatol 2016; 28: 123-31.
  5. Palmela C, Peerani F, Castaneda D, et al. Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. Gut Liver 2018; 12: 17-9.
  6. van Munster KN, Bergquist A, Ponsioen CY. Inflammatory bowel disease and primary sclerosing cholangitis: one disease or two? J Hepatol 2024; 80: 155-68.
  7. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012; 56: 1181-8.
  8. Rabiee A, Silveira MG. Primary sclerosing cholangitis. Transl Gastroenterol Hepatol 2021; 6: 29.
  9. Culver EL, Bungay HK, Betts M, et al. Prevalence and long-term outcome of sub-clinical primary sclerosing cholangitis in patients with ulcerative colitis. Liver Int 2020; 40: 2744-57.
  10. Barberio B, Massimi D, Cazzagon N, et al. Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis. Gastroenterology 2021; 161: 1865-77.
  11. Trivedi PJ, Crothers H, Mytton J, et al. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age. Gastroenterology 2020; 159: 915-28. Weismüller TJ, Strassburg CP, Trivedi PJ, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017; 152: 1975-84.e8.
  12. De Groof EJ, Rossen NGM, Van Rhijn BD, et al. Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands. Eur J Gastroenterol Hepatol 2016; 28: 1065-72.
  13. Imbrizi M, Magro F, Coy CSR. Pharmacological therapy in inflammatory bowel diseases: a narrative review of the past 90 years. Pharmaceuticals 2023; 16: 1272.
  14. Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Front Med 2021; 8: 765474.
  15. Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009; 33: 854-62.
  16. Sano H, Nakazawa T, Ando T, et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci 2011; 18: 154-61.
  17. De Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol 2015; 21: 1956-71.
  18. Wang MH, Mousa OY, Friton JJ, et al. Unique phenotypic characteristics and clinical course in patients with ulcerative colitis and primary sclerosing cholangitis: a multicenter US experience. Inflamm Bowel Dis 2020; 26: 774-9.
  19. Jørgensen KK, Grzyb K, Lundin KEA, et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: cinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012; 18: 536-45.
  20. Ricciuto A, Kamath BM, Griffiths AM. The IBD and PSC phenotypes of PSC-IBD. Curr Gastroenterol Rep 2018; 20: 16.
  21. Boonstra K, Van Erpecum KJ, Van Nieuwkerk KMJ, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2270-6.
  22. Krugliak Cleveland N, Rubin DT, Hart J, et al. Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal colon. Clin Gastroenterol Hepatol 2018; 16: 68-74.
  23. Nakazawa T, Naitoh I, Hayashi K, et al. Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity? World J Gastroenterol 2014; 20: 3245-54.
  24. Loftus EV, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-6.
  25. Schaeffer DF, Win LL, Hafezi-Bakhtiari S, et al. The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis. Dig Dis Sci 2013; 58: 2608-14.
  26. Sokol H, Cosnes J, Chazouilleres O, et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 2008; 14: 3497-503.
  27. Halliday JS, Djordjevic J, Lust M, et al. A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn’s disease. J Crohns Colitis 2012; 6: 174-81.
  28. Marelli L, Xirouchakis E, Kalambokis G, et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011; 60: 1224-8.
  29. Chazouilleres O, Beuers U, Bergquist A, et al. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol 2022; 77: 761-806.
  30. Gordon H, Biancone L, Fiorino G, et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis 2023; 17: 827-54.
  31. Ananthakrishnan AN, Cagan A, Gainer VS, et al. Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis 2014; 8: 956-63.
  32. Zheng HH, Jiang XL. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. Eur J Gastroenterol Hepatol 2016; 28: 383-90.
  33. Broomé U, Löfberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-8.
  34. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patiets with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54.
  35. Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006; 26: 31-41.
  36. Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58: 2045-55.
  37. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160: 1570-83.
  38. Carrat F, Seksik P, Colombel JF, et al. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2017; 45: 533-41.
  39. Shah A, Jones MP, Callaghan G, et al. Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: a systematic review and meta-analysis. Hepatol Commun 2024; 8: e0347.
  40. Huynh D, Rubtsov D, Khaing MM. Efficacy of biologics in the treatment of primary sclerosing cholangitis associated with inflammatory bowel disease: a systematic review and meta-analysis. Cureus 2024; 16: e56182.
  41. Alipour O, Gualti A, Shao L, Zhang B. Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFa in inflammatory bowel disease. BMC Gastroenterol 2021; 21: 312.
  42. Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol 2018; 53: 1048-64.
  43. Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol 2016; 7: e135.
  44. Peyrin-Biroulet L, Danese S, Argollo M, et al. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with crohn’s disease or ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2019; 17: 838-46.e2.
  45. Schregel I, Ramos GP, Ioannou S, et al. Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: a multicenter, retrospective study. Clin Gastroenterol Hepatol 2023; 21: 3448-50.e3.
  46. Lynch KD, Chapman RW, Keshav S, et al. Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. Clin Gastroenterol Hepatol 2020; 18: 179-87.e6.
  47. Caron B, Peyrin-Biroulet L, Pariente B, et al. Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID Multicentre Cohort Study. J Crohns Colitis 2019; 13: 1239-47.
  48. Hedin CRH, Sado G, Ndegwa N, et al. Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2020; 18: 2295-304.e2.
  49. Christensen B, Micic D, Gibson PR, et al. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther 2018; 47: 753-62.
  50. Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterol 2022; 22: 291.
  51. Kanizaj TF, Mijic M. Inflammatory bowel disease in liver transplanted patients. World J Gastroenterol 2017; 23: 3214-27.
  52. Ho GT, Seddon AJ, Therapondos G, et al. The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol 2005; 17: 1379-85.
  53. Saldeen K, Friman S, Olausson M, et al. Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis. Scand J Gastroenterol 1999; 34: 535-40.
  54. Gavaler JS, Delemos B, Belle SH, et al. Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Dig Dis Sci 1991; 36: 321-8.
  55. Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transpl 2006; 6: 1422-9.
  56. Calmet FH, Yarur AJ, Pukazhendhi G, et al. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation. Ann Gastroenterol 2015; 28: 366-73.
  57. Lumbreras C, Manuel O, Len O, et al. Cytomegalovirus infection in solid organ transplant recipients. Clin Microbiol Infect 2014; 20 (suppl 7): 19-26.
  58. Altwegg R, Combes R, Laharie D, et al. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: a nationwide case series. Dig Liver Dis 2018; 50: 668-74.
  59. Holvoet T, Verstockt B, Lenfant M, et al. P621 Safety and effectiveness of vedolizumab and ustekinumab in inflammatory bowel disease patients after liver transplantation for primary sclerosing cholangitis: results from an ECCO-confer case series. J Crohn’s Colitis 2024; 18 Suppl 1: i1195-6.
  60. Con D, Hilley P, Chin S, et al. Safety and effectiveness of janus kinase inhibitors in the management of inflammatory bowel disease following liver transplantation. J Crohns Colitis 2024; 18: 1505-9.
  61. Al Draiweesh S, Ma C, Alkhattabi M, et al. Safety of combination biologic and antirejection therapy post-liver transplantation in patients with inflammatory bowel disease. Inflamm Bowel Dis 2020; 26: 949-59.
  62. Spadaccini M, Aghemo A, Caprioli F, et al. Safety of vedolizumab in liver transplant recipients: a systematic review. United European Gastroenterol J 2019; 7: 875-80.
  63. van Meeteren MJW, Hayee B, Inderson A, et al. Safety of anti-TNF treatment in liver transplant recipients: a systematic review and metaanalysis. J Crohns Colitis 2017; 11: 1146-51.
  64. Singh S, Loftus EV, Talwalkar JA. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol 2013; 108: 1417-25.
  65. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006; 12: 1813-24.
  66. van de Vrie W, de Man RA, van Buuren HR, et al. Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2003; 15: 657-63.
  67. Mosli M, Croome K, Qumosani K, et al. The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease. Gastroenterol Hepatol 2013; 9: 434-41.
  68. Peverelle M, Paleri S, Hughes J, et al. Activity of inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis predicts poorer clinical outcomes. Inflamm Bowel Dis 2020; 26: 1901-8.
  69. Joshi D, Bjarnason I, Belgaumkar A, et al. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int 2013; 33: 53-61.
  70. Lindström L, Jørgensen KK, Boberg KM, et al. Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study. Scand J Gastroenterol 2018; 53: 297-304.
  71. Ravikumar R, Tsochatzis E, Jose S, et. Al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol 2015; 63: 1139-46.
  72. Gelley F, Zádori G, Görög D, et al. Recurrence of primary sclerosing cholangitis after liver transplantation-The Hungarian experience. Interv Med Appl Sci 2014; 6: 16-8.
  73. Moncrief KJ, Savu A, Ma MM, et al. The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation--a single-centre experience. Can J Gastroenterol 2010; 24: 40-6.
  74. Alexander J, Lord JD, Yeh MM, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008; 14: 245-51.
  75. Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008; 14: 138-43.
  76. Alabraba E, Nightingale P, Gunson B, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009; 15: 330-40.
  77. Kim YS, Hurley EH, Park Y, Ko S. Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease. Intest Res 2023; 21: 420-32.
  78. Floreani A, De Martin S. Treatment of primary sclerosing cholangitis. Dig Liver Dis 2021; 53: 1531-8.
  79. Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015; 62 (Suppl 1): S25-37.
  80. Fickert P, Hirschfield GM, Denk G, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 2017; 67: 549-58.
  81. Trauner M, Gulamhusein A, Hameed B, et al. The nonsteroidal farnesoid X receptor agonist Cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology 2019; 70: 788-801.
  82. Trauner M, Chung C, Sterling K, et al. PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis. BMC Gastroenterol 2023; 23: 75.
  83. Zimmermann HW, Tacke F. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets 2011; 10: 509-36.
  84. Eksteen B, Bowlus CL, Montano-Loza AJ, et al. Efficacy and safety of cenicriviroc in patients with primary sclerosing cholangitis: PERSEUS study. Hepatol Commun 2020; 5: 2021.
  85. Arndtz K, Corrigan M, Rowe A, et al. Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): a single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol. BMJ Open 2017; 7: e015081.
  86. Stokkeland K, Höijer J, Bottai M, et al. Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2019; 17: 1860-6.e1.
  87. Bergquist A, Marschall HU, Nilsson E, et al. Long term effect of simvastatin in primary sclerosing cholangitits: a placebo-controlled, double-blind, multicenter phase III study (Piscatin). Br J Gastroenterol 2022; 4: 235-41.
  88. Hole MJ, Jørgensen KK, Holm K, et al. A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation. Hepatology 2023; 77: 715-28.
  89. Allegretti JR, Kassam Z, Carrellas M, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol 2019; 114: 1071-9.
  90. Vleggaar FP, Monkelbaan JF, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol 2008; 20: 688-92.
  91. Abarbanel DN, Seki SM, Davies Y, et al. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol 2013; 33: 397-406.
  92. Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 2013; 37: 604-12.
  93. Arbabzada N, Dennett L, Meng G, Peerani F. The effectiveness of oral vancomycin on inflammatory bowel disease in patients with primary sclerosing cholangitis: a systematic review. Inflamm Bowel Dis 2025; 31: 8027-35.

Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
without publication fees